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We explored suitability of a rat tuberculosis aerosol infection model for investigating the pharmacodynamics of new
antimycobacterial agents. Infection of rats via the aerosol route led to a reproducible course of M. tuberculosis infection in the
lungs. The pulmonary bacterial load increased logarithmically during the ﬁrst six weeks, thereafter, the infection stabilized for the
next 12 weeks. We observed macroscopically visible granulomas in the lungs with demonstrable acid-fast bacilli and associated
histopathology. Rifampicin (RIF) at a dose range of 30 to 270mg/kg exhibited a sharp dose response while isoniazid (INH) at a
dose range of 10 to 90mg/kg and ethambutol (EMB) at 100 to 1000mg/kg showed shallow dose responses. Pyrazinamide (PZA)
had no dose response between 300 and 1000mg/kg dose range. In a separate time kill study at ﬁxed drug doses (RIF 90mg/kg,
INH 30mg/kg, EMB 300mg/kg, and PZA 300mg/kg) the bactericidal eﬀect of all the four drugs increased with longer duration
of treatment from two weeks to four weeks. The observed infection proﬁle and therapeutic outcomes in this rat model suggest
that it can be used as an additional, pharmacologically relevant eﬃcacy model to develop novel antitubercular compounds at the
interface of discovery and development.
1.Introduction
Tuberculosis remains a leading cause of death worldwide [1]
despite unprecedented interest in the scientiﬁc community
to better understand the pathobiology and development of
newer interventional therapies. In this process, animal mod-
els of infection have been a corner stone in understanding
complexpathologyandimmunologyoftuberculosis.Guinea
pigs were the ﬁrst animal models used to demonstrate
tuberculosisdiseasebyKochin1882[2].Sincethen,avariety
of animal models including mice, rabbits, and nonhuman
primates [3–5] have been investigated to simulate tubercular
disease and associated host responses. However, none of
the models can mimic the complex pathobiology seen in
humans.
The mouse continues to be a preferred species for
modelingtuberculosisinfectionaswellasforscreeningnovel
anti-TB drug candidates due to practical reasons [6, 7].
Guinea pigs, rabbits, and nonhuman primates are known
to be better representatives of late human disease [4, 5]b u t
pose a challenge for drug screening due to large compound
requirements and prohibitive costs.
Ratshavesigniﬁcantlycontributedtomodelingofvariety
of human pulmonary bacterial [8], fungal [9]a n dv i r a l
infections [10, 11] due to an increasing availability of rat
immunological reagents. In recent years, several rat strains
like Lewis, American cotton rats [12], and diabetic rat strains
[13] have been successfully used to develop infection model
of tuberculosis, particularly for investigating pathology and
immune responses [14, 15]. However, there are no reports
on therapy of tuberculosis in rat infection model. Here we
report the application of Wistar rat model for approximating
tuberculosisinfectionandtheeﬀectoffront-linedrugsinthe
containment of this infection.
2.MaterialandMethods
2.1. Bacterial Strain. M. tuberculosis H37Rv ATCC 27294, a
strain sensitive to all the standard antimycobacterial agents,2 International Journal of Microbiology
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Figure 1: Standardisation of M. tuberculosis aerosol infection in
Wistar rats: initial bacillary load and course of infection observed
over a period of 4 weeks, following challenge with three diﬀerent
infection inocula.
was used for all animal infection experiments. Bacterial
cultures were prepared as described previously [16].
2.2. Drugs and Reagents. Rifampicin (RIF), Isoniazid (INH),
Pyrazinamide (PZA), Ethambutol (EMB), and Carboxym-
ethyl cellulose (CMC) were purchased from Sigma Chemical
Co. USA.
2.3. Animals. The Institutional Animal Ethics Committee
(IAEC), registered with the Government of India (Reg.
no. 5/1999/CPCSEA) approved all animal experimental
protocols and usage. Male Wistar rats were purchased from
RajBiotechPune,India.Rats(7–8weeksold)wererandomly
assigned into groups of three per cage and were allowed
2 weeks acclimatisation before experimental use. Feed and
water were given ad libitum. Infected rats were maintained in
individually ventilated cages (Allentown technologies, USA)
in bio containment level 3 facilities.
2.4. Aerosol Infection. Wistar rats were infected via the
respiratoryroutetoobtainlow-gradebacillarylunginfection
(∼100 bacilli) using a modiﬁed Madison aerosol chamber
[16]. Bacterial lung loads were estimated to determine
suitable infection conditions for drug eﬃcacy experiments.
After infection, the animals were housed for the duration of
the study in a bio-safety level 3 facilities. By using micro-
bial enumeration as the dependent variable, the number
of animals required per treatment group was as low as
three in experiments for drug evaluation. The course of
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Figure 2: Course of infection of M. tuberculosis H37Rv in Rat lungs
following low-grade aerosol infection. (): Course of infection and
CFUobtainedduringweeks1–7instudy1.():Courseofinfection
and CFU obtained over weeks 2–18 in study 2. Drug treatment
started at week 4 postinfection. Inset shows a rat lung at thirteen-
weekpostinfectionwithmultiplemacroscopicnodulargranulomas
all the lung lobes following aerosol infection with M. tuberculosis.
mycobacterial infection was monitored by enumeration of
colony forming units (CFU) from excised lungs at 1, 2, 3,
4, 6, 8,13, and 18 weeks postinfection.
2.5. In Vivo Dose-Response Studies. In a separate experiment,
starting 4 weeks postinfection, 3 animals per group were
administered by oral gavage once daily with a dose range of
front-lineanti-TBdrugsina0.25%(w/v)carboxymethylcel-
lulose suspension formulation. Rifampicin (30–270mg/kg),
Isoniazid (10–90mg/kg), Pyrazinamide (300–1000mg/kg),
and Ethambutol (100–1000mg/kg) were administered for
two or four weeks. At the onset and 24h after the completion
of treatment, groups of rats were killed by exposure to CO2
and the lungs were aseptically removed. Left lung lobe was
processed for CFU estimation to monitor drug eﬃcacy while
the right lobe was ﬁxed in 10% formaldehyde solution for
histopathology. The left lung lobe was homogenized in a
ﬁnal volume of 3mL by using Teﬂon-Glass tissue grinders
(Wheaton Inc.). Each suspension was serially diluted in
10-fold steps, and at least 3 dilutions were plated onto
Middlebrook 7H11 agar supplemented with 10% albumin
dextrose catalase (Difco Laboratories) and incubated at 37
◦C
with 5% CO2 for 3 weeks.
2.6. Histopathology. The right lung lobe of each animal was
removed for histopathological studies. They were inﬁltratedInternational Journal of Microbiology 3
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Figure 3: Dose response of front-line TB drugs in rats following
two-weektreatment.log10 CFUcounts/leftlunglobeplottedagainst
a range of drug regimens. Rifampicin (30, 90 and 270mg/kg),
Isoniazid (10, 30, and 90mg/kg), Ethambutol (100, 300, and
1000mg/kg) and Pyrazinamide (300 and 1000mg/kg) were dosed
per oral once daily for two weeks (12 doses). Each bar represents
the mean CFU counts from three animals.
with and collected in 10% buﬀered neutral formalin, fol-
lowed by standard histopathological processing techniques
[15] using diﬀerent gradation of alcohol. Paraﬃne m b e d d e d
tissues were sectioned to 5μm thickness and stained with
either Haematoxyline and Eosin stain or Ziehl Neilson
staining for acid fact bacilli using quick staining kit (Becton-
Dickinson).
2.7. Statistical Analysis. The colony counts obtained from
plating were transformed to log10(x+1), where x equals the
totalnumberofviabletuberclebacillicalculatedtobepresent
in a given sample. Prism software version 4 (GraphPad
Software, Inc., San Diego, California) was used for all the
calculations.
3. Results
3.1.CourseofM.tuberculosisInfectioninRatLung. Thefocus
of initial experiments was to establish an optimum inoculum
size required to consistently achieve low bacterial numbers
(100–300CFU) in the lungs. M. tuberculosis inocula of three
diﬀerent bacterial strengths (104 CFUmL
−1), 106 CFUmL
−1
and 108 CFUmL−1) were aerosolised in a 25mL volume
using a Collison Nebulizer (BGI Incorporated, Waltham,
MA) for a ﬁxed duration, and the course of infection
was monitored till four weeks. All three inocula lead to
installation of bacilli into the lungs in a dose-dependent
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Figure 4: Time course of eﬀect of front-line TB drugs on rat lung
infection (RIF-90mg/kg; INH-30mg/kg; EMB 300mg/kg and PZA
300mg/kg).Drugtreatmentwasgivenperoraloncedailyfor2-and
4-week periods.
manner (Figure 1). An inoculum of 106 CFU mL−1 con-
sistently delivered ∼ 200 bacilli/lung and was considered
optimum for further experiments. The course of infection
following an initial load of 108 CFU mL−1 was steep, while
that following 104 CFU mL−1 yielded inconsistent infection
across animals. Thus these two inocula were not preferred
for further experiments. The course of tuberculosis infection
increased logarithmically up to the ﬁrst 6 weeks. The growth
rate declined thereafter and the net bacterial load in the
lungs increased by merely 1 Log10CFU over the next 12-week
period (Figure 2).
3.2. Gross and Histopathology Findings. Grossly the rats
developed circumscribed granuloma of varying sizes (pin-
point to 3mm in diameter) distributed over the lung
surface by 6 weeks and gradually increased to 5mm and
showed raised appearance (Figure 2 inset). Histopatholog-
ical examination of the granuloma at various intervals
during the course of infection revealed strong association
between bacillary loads and pathology. Microscopically,
for the ﬁrst two weeks there were no histopathological
changes in the lungs except for mild inﬂammatory response
in the blood vessel. By week 2, there was mononuclear
cell inﬁltration in alveolar spaces distributed sparsely in
lower inoculum (104 CFUmL
−1) and extensively in higher
inoculum groups (106 CFUmL−1 and 108 CFUmL−1). By 4
weeks, granulomatous lesions were seen in lungs across all
groups (Figure 5), although the number of such foci varied
depending on the initial inoculum. The predominant cell
types were macrophages/histiocytes and foam cells. Lym-
phocytic aggregation was predominant while few epitheloid
cells and multinucleated histiocytes were seen occasionally.
Some degenerating neutrophils were also seen. There was no
central zone of necrosis and peripheral ﬁbrosis. The general
architecture of granuloma resembled that seen in mice.4 International Journal of Microbiology
Table 1: Reproducibility of infection and response to treatment across 2 independent experiments. Each data point represents the mean ±
SD data from three animals per group.
log10 CFU/Lung
Untreated RIF-90 INH-30 EMB-300 PZA-300
Expt.1 Mean 4.75 2.63 3.45 4.51 4.13
Std. Dev. 0.42 0.21 0.01 0.39 0.03
Expt.2 Mean 4.94 2.86 3.82 4.78 4.52
Std. Dev. 0.21 0.11 0.03 0.02 0.35
(a)
10μm
(b)
Figure 5:H&Eat100×magniﬁcation(a)andZNstainat1000×magniﬁcation(b)ofalunggranulomatouslesionat4weekspostinfection.
3.3. Bactericidal Activity of Drugs. The dose response of four
frontlineTBdrugswasdeterminedintheratinfectionmodel
over a wide concentration range administered once daily
per-orally for 2 weeks. RIF exhibited most potent and a
sharp dose-dependent bactericidal activity among all drugs
tested (Figure 3). RIF 30, 90, and 270 mg/kg doses resulted
in 1.5, 2.1, and 2.7-log10 CFU reductions, respectively, in
the lungs following two weeks of treatment. INH was the
secondmosteﬃcaciousdrugwith0.4,1.2,and1.3-log10 CFU
reductions, respectively, at 10, 30, and 90 mg/kg doses. EMB
w a sl e s se ﬃcacious than RIF and INH but exhibited a clear
dose response. The net bactericidal eﬀect of EMB 100, 300
and 1000mg/kg was 0.1, 0.2 and 0.9-log10 CFU reductions,
respectively.Incontrast,PZAhadactivityof0.6and0.7-log10
CFU reductions at 300 and 1000mg/kg doses.
In a second experiment, we compared the eﬀect of
RIF 90mg/kg, INH 30mg/kg, EMB 300mg/kg, and PZA
300mg/kg administered per-orally once daily either for 2
weeks or 4 weeks. The eﬀect was reproducible across the
two experiments (Table 1); RIF, EMB, and PZA exhibited
signiﬁcantly higher bactericidal activity when the duration
of treatment was increased from 2 to 4 weeks, while INH did
not (Figure 4).
4. Discussion
Animal models are an integral part of drug discovery
programs. They allow understanding of disease process and
evaluation of new interventions in a dynamic system thus
providing a link between in vitro potency and therapeutic
use.
Traditionally, mice have been the model of choice for
early preclinical testing of drug candidates for antitubercular
activity because of their relative ease in handling, lower
maintenance costs, and need for small amounts of experi-
mental drugs to study pharmacokinetics and pharmacody-
namics [6, 7, 17]. In contrast, rats have been considered
unsuitable for experimental tuberculosis since they were
noted to be resistant to tubercle bacilli. Neither high doses
of tubercle bacilli given parenterally could kill nor produce
necrotic tuberculous lesions and tuberculin sensitivity.
ThepathologyobservedinmicefollowingM.tuberculosis
infection does not entirely reﬂect the human disease. In con-
trast, larger animals like guinea pigs, rabbits, and nonhuman
primates better approximate human tuberculosis [18–21].
However, the obvious limitation for drug screening remains
the larger size, logistics and drug quantity requirements. InInternational Journal of Microbiology 5
recent years, evidence is available where tuberculosis infected
rats have necrotic lesions and chronic infections in the
lungs [13, 14, 22], that are closer to the events observed
in human disease than in the mice model. Thus, rats may
provide an intermediate option in terms of representing
more histopathological aspects of human disease than mice,
yet not posing signiﬁcantly higher demands on logistics and
drug substance.
We report a Wistar rat aerosol infection model of tuber-
culosis suitable for investigating the pharmacodynamics of
antitubercular drugs. Three key reasons that prompted us to
explore a rat infection model are as follows.
(1) Rats are widely accepted species for investigating
pharmacokinetics and toxicokinetics at the pre-
clinical and development stages of drug discovery
programs [15].
(2) In recent years, there are many reports on rat
M. tuberculosis infection models for investigating
immunology and pathology of tuberculosis [12–15,
19]. A report indeed showed that granulomas in
M. tuberculosis infected American cotton rats [12]
exhibit caseous central necrosis similar to humans
thereby adding additional value to the animal model.
(3) We reasoned that if the response of M. tuberculosis
infectedratstoantituberculartherapyisreproducibly
established then the entire PK, PD, and toxicological
investigations at the interface of discovery and devel-
opment can be done in the same species.
We have reproducibly achieved chronic rat lung infec-
tions similar to that reported in American Cotton rats [12]
and Lewis rats [14]. In our study, infected rats appeared
healthyduringthe18weeksofobservation.Aerosolinfection
allowed us to mimic portal of entry as in humans, resulting
in inﬂammatory disease leading to pulmonary granulomas.
The biphasic nature of infection may provide an opportunity
to study drug eﬀectson actively replicating bacilli (week 1–6)
or on minimally replicating bacilli (week 7–18).
The histopathological changes observed in Wistar rats
over a period of 18 weeks had no central necrosis similar
to mice [7] and other rat strains like type 1 diabetic rats
[13]a n dL e w i sr a t s[ 14]. In contrast, American cotton
rats [12] and F344/N-rnu nude rats [22] have been shown
to exhibit central necrosis within granulomas suggesting
variable immunological and pathological outcomes across
diﬀerent rat strains.
Ourstudyestablishedeﬃcacyoffourfront-line TBdrugs
(RIF,INH,PZA,andEMB)intheWistarratinfectionmodel.
Signiﬁcant bactericidal activities of four reference drugs
acting on distinct molecular targets undoubtedly suggest
suitabilityofratinfectionmodelforscreeningofcompounds
with antitubercular activity. Thus, Wistar rat model oﬀers a
signiﬁcant advantage over the mouse model since it presents
histopathological changes that are closer to that observed
in human tuberculosis, while simultaneously permitting the
study of pharmacokinetics, pharmacodynamics, and safety
pharmacology in the same species. This would provide
a better handle in terms of predicting the human dose with
the appropriate safety margins.
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